Kymera Therapeutics on X

Advancing the field of targeted protein degradation to deliver breakthrough medicines for previously untreatable diseases.

Kymera Therapeutics - X

Today we shared new clinical data being presented at the @EHA_Hematology Annual Meeting from our ongoing KT-333 Phase 1 oncology trial.

Kymera Therapeutics to Report Third Quarter 2024 Financial ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address ...

Kymera Therapeutics: Revolutionary Medicines Catalyzed by ...

Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.

X-Chem and Kymera Expand Existing Partnership

With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera — with X- ...

Kymera Therapeutics Announces Third Quarter 2024 Financial ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address ...

Kymera Therapeutics Announces FDA Clearance of Investigational ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address ...

Press Releases - Kymera Therapeutics, Inc.

November 05, 2024. Kymera Therapeutics to Participate in Upcoming November Investor Conferences · October 31, 2024. Kymera Therapeutics Announces Third Quarter ...

Kymera Therapeutics - X

Today we recognize #AtopicEczemaDay and hope to increase awareness and understanding for this chronic, inflammatory condition and the ...

Kymera Therapeutics to Participate in Upcoming May Investor ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health ...

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD ...

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. ... X (previously Twitter) or LinkedIn. Cautionary Note ...

Our Approach - Kymera Therapeutics

Pioneering Targeted Protein Degradation to Invent New Medicines ... Kymera's pipeline is focused on deploying TPD against disease targets within highly validated ...

Kymera Therapeutics to Participate in Upcoming September Investor ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address ...

Kymera Therapeutics to Report Second Quarter 2024 Financial ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address ...

Kymera Therapeutics Starts Phase 1 Trial of KT-621 with First ...

(NASDAQ: KYMR), a biopharmaceutical company in the clinical development stage that is pioneering a novel category of small molecule therapies ...

Kymera Therapeutics - Drug Discovery World (DDW)

X-Chem and Kymera Therapeutics have expanded their collaboration, which will now comprise 12 targets and grants Kymera exclusive rights to ...

Kymera Therapeutics Announces Closing of Upsized $225 Million ...

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to ...

WilmerHale Advises Underwriters in Follow-on Public Offering of ...

Kymera received approximately $316.2 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related ...

Kymera Therapeutics to Report Third Quarter 2024 Financial ...

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address ...

Kymera Therapeutics Announces Pricing of $225 Million Public ...

Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that ...